NASDAQ · Biotechnology

CLRB (CLRB) Stock

$2.37 -2.07% NASDAQ: CLRB Healthcare

Valuation

MetricValue
Price$2.37
Market Cap$7.57M
P/E Ratio-0.38
P/B Ratio1.01
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$10.19
52-Week Low$2.20
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-220.00%
ROA-146.67%
ROCE-230.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.32
Current Ratio2.80

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-24.0M$-29.0M$-39.0M$-52.0M$-23.0M
Net Profit$-24.0M$-32.0M$-43.0M$-45.0M$-22.0M
EPS$-130.35$-135.18$-104.99$-41.89$-8.35
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$37.0M$22.0M$12.0M$25.0M$15.0M
Total Liabilities$4.0M$12.0M$26.0M$11.0M$5.0M
Cash$36.0M$20.0M$10.0M$23.0M$13.0M
Borrowings$0$1.0M$1.0M$0$0

Latest News

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers GlobeNewswire · Jul 15, 2026 Cellectar Biosciences (CLRB) Stock Fair Value Moves Lower As Analysts Weigh Execution Risk Simply Wall St. · Jul 11, 2026 Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting GlobeNewswire · Jun 1, 2026 Cellectar Biosciences Files for Secondary Offering of Common Shares MT Newswires · May 19, 2026 Cellectar Biosciences Inc (CLRB) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ... GuruFocus.com · May 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-23.0M$-25.0M$-32.0M$-48.0M$-23.0M
Investing Cash Flow$0$0$-2.0M$0$0
Financing Cash Flow$1.0M$-10.0M$1.0M$0$0
Net Cash Flow$-21.0M$-16.0M$-10.0M$14.0M$-10.0M
Free Cash Flow$-23.0M$-25.0M$-33.0M$-48.0M$-23.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-181.99%
Quick Ratio1.90
Interest Coverage—
Return 1Y-45.40%
Return 3Y-95.27%
Return 5Y-99.20%

Ownership

Insiders Held2.07%
Institutions Held16.66%
Institutions Float Held17.01%
Institutional HolderSharesReport Date
Bleichroeder LP100,0002026-03-31
Vanguard Capital Management LLC81,8842026-03-31
Geode Capital Management, LLC52,7782026-03-31
Sequoia Financial Advisors, LLC21,8502026-06-30
Vanguard Fiduciary Trust Co16,5732026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AEONAEON Biopharma, Inc. $0.24 -5.50% -0.05 $2.80M 0.00%
BOLT $3.95 -0.50% -0.26 $7.59M 0.00%
CING $4.52 -2.59% -1.08 $25.34M 0.00%
EVGNEvogene Ltd. $0.54 -0.04% -0.41 $4.67M 0.00%
IMNN $1.53 +0.00% -0.31 $3.86M 0.00%

About CLRB

CLRB is led by CEO James V. Caruso, employs 11 people, headquartered in US, publicly traded since 2005.

CLRB stock trades at $2.37 with a market capitalization of $7.57M. The stock is valued at a price-to-earnings (P/E) ratio of -0.38, price-to-book of 1.01, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.20 and $10.19, and currently trades 76.7% below its 52-week high.

On profitability, CLRB generates a return on equity (ROE) of -220.00%, return on capital employed of -230.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides